Abstract: A method for disoriented cell configuration includes collecting user data of a first set of cells, determining a disoriented cell of the first set of cells based on the user data, and changing a configuration of an antenna of the disoriented cell. Changing the configuration of the antenna of the disoriented cell includes changing the deployed azimuth of the antenna to be equal to the planned azimuth of the antenna. The user data includes received signal strength of a first set of users, geolocation data of the first set of users, or a cell identifier of a corresponding cell of the first set of cells. The disoriented cell of the first set of cells includes a node with an antenna with a deployed azimuth. The disoriented cell of the first set of cells corresponds to a filtered first set of qualified geolocation data of a filtered second set of users.

Abstract: A method for disoriented cell configuration includes determining a first number of misaligned sectors in a first set of disoriented cells of a first set of cells, generating data of a second set of disoriented cells based on the first set of disoriented cells or the first number of misaligned sectors for in the first set of disoriented cells, determining a first set of cross-feeder cells, a first set of sector swap cells or a first set of cyclic swap cells, and changing a configuration of an antenna of a disoriented cell of the second set of disoriented cells. Changing the configuration of the antenna includes changing a connection of a set of cables of an antenna of a first cross-feeder cell, or changing a deployed azimuth of an antenna of a sector in the first set of sector swap cells or cyclic swap cells.

Abstract: Providing overload protection may include receiving, from a first NRF of two or more NRFs, a load metric and comparing the load metric to a threshold. Additionally, when the load metric is above the threshold, providing NRF overload protection may include sending a Network Function (NF) Discovery (NFD) message to a second NRF instead of the first NRF and sending a heartbeat signal to the first NRF.

Abstract: A method is provided for the acute treatment of migraine headaches with or without aura by injecting dihydroergotamine mesylate into a subject. The method includes storing the dihydroergotamine mesylate in an autoinjector at room temperature in a foil pouch. The method further includes removing the autoinjector from the pouch; removing a cap of the autoinjector; pushing the autoinjector down against an injection site of the subject to depress a safety guard; pressing and releasing an activation button on the autoinjector to start injection; and holding the autoinjector against the injection site for at least 10 seconds irrespective of whether a click is generated. The method further includes confirming that the injection is complete by viewing a change of color in a viewing window of the autoinjector, and lifting the autoinjector up away from the injection site and allowing the guard to drop down and lock over a needle.

Abstract: An acceptable coverage limit of a base station is identified by retrieving a list of cells that are served by a first base station. Grids are generated from the first base station to a predetermined threshold distance. A plurality of selected grids is identified between an acceptable coverage limit and a threshold distance. An average reference signal is determined from the plurality of selected grids. An evaluation is made regarding whether the first base station is the dominant cell in each of the selected grids. The number of grids the selected grids where the first base station is the dominant cell site is determined based on a dominant carrier threshold. A column of grids is determined where the first base station is not the dominant cell site. An acceptable coverage limit of the cell is determined based on the distance from the first base station and the column of grids.

Abstract: A cell range determination is made by determining a sector straddling an azimuth line of a first base station with a center at the coordinates of a first base station. The sector is divided into a plurality of subsectors. A nearest neighbor base station is determined in each of the plurality of subsectors. A set of coordinates is determined for the nearest neighbor base station. An average distance between the nearest neighbor base stations is determined. A bearing angle difference between the nearest neighbor base station and the first base station is determined based on the set of coordinates of the nearest neighbor base station. A gain is determined for each of the plurality of subsectors based on the bearing angle difference. A cell range is determined for the first base station based on the gain.

Abstract: A booming cell start distance and recommended electronic tilt is identified by retrieving a list of cells served by a first base station. A plurality of grids is generated from the first base station to a predetermined threshold distance. A plurality of selected grids is identified between an acceptable coverage limit and a threshold distance. An evaluation is made regarding whether the first base station is not the dominant cell in each of the selected grids based. The number of grids where the first base station is not the dominant cell site is determined based on a dominant carrier threshold. A column of grids where the first base station is no longer the dominant cell site is determined based on the dominant carrier threshold. A bad booming distance of the cell is determined based on the distance from the first base station and the determined column of grids.

Abstract: Oligonucleotides, methods and kits are provided for detecting, identifying or quantifying one or more target analytes in a sample as well as methods for immobilizing oligonucleotides onto a support surface.

Abstract: A booming cell site is identified in a cloud native environment by retrieve an on-air base station from a site database, retrieve a timing advance distribution (TAD) key performance indicator data for a cell site served by the on-air base station from the list, determine a count of configured gaps for the cell site in the timing advance distribution key performance indicator data, determine a count of booming samples that lie beyond the configured count of gaps for the cell site based on the timing advance distribution key performance indicator data, determine a sum of the timing advance distribution key performance indicator data available for the cell site, and determine the percentage of booming cells based on the count of booming samples and the sum of the timing advance distribution key performance indicator.

Abstract: A method of providing and/or injecting octreotide acetate to a subject in need thereof includes storing the octreotide acetate in a cartridge of a multi-use multi-dose injector provided with a variable dose setter and actuator. The injector includes a needle configured for subcutaneous administration of the octreotide acetate, the octreotide acetate having a concentration of 2,500 ?g/mL. The method further includes permitting setting of a dose of the octreotide acetate by rotation of the variable dose setter. The injector is configured to provide at least one audible feedback during the rotation. The method further includes operating the actuator to deliver the octreotide acetate from the cartridge through the needle to treat the subject. The injector is provided with multiple surface portions.

Abstract: Example systems and methods provide input suggestions to a user to improve user experience on user devices. The input suggestions can be fill information from another app on device to the present app being used by user, information for performing a search (without the user having to copy-paste data or entering the data manually), responses to a message/notification received by the user, information/content/data to be shared between apps (without switching between apps), and emojis/GIFs that can be used by the user. The method includes analyzing one or more content of one or more screen displayed on device, generating at least one of a logical tree structure and a data mashup model of the one or more analyzed content for each screen, and providing a recommendation to a user. The recommendation can be a connected action or an input suggestion.

Abstract: The present invention relates to methods and kits to assess an absorbed dose of ionizing radiation and/or the severity of tissue injury from radiation in a patient. The invention also relates to algorithms used to calculate an absorbed dose of radiation based on biomarker measurements of a plurality of biomarkers that are altered relative to a normal control in the event of radiation exposure.

Abstract: A method of providing and/or injecting octreotide acetate to a subject in need thereof includes storing the octreotide acetate in a cartridge of a multi-use multi-dose injector provided with a variable dose setter and actuator. The injector includes a needle configured for subcutaneous administration of the octreotide acetate, the octreotide acetate having a concentration of 2,500 ?g/mL. The method further includes providing, on the injector, a plurality of indicia only at prescribed doses of 50 ?g, 100 ?g, 150 ?g and 200 ?g settable via the dose setter without indicia between said prescribed doses; and permitting setting of a dose of the octreotide acetate by rotation of the variable dose setter, wherein the injector is configured to provide at least one audible feedback during the rotation.

Abstract: The invention relates to methods and kits for quantitating radiation exposure in a subject exposed to radiation, at risk of exposure to radiation or suspected of having been exposed to radiation. In embodiments, the present disclosure provides multiplexed immunoassays for quantifying amounts of biomarkers for assessing radiation exposure in a sample. Also provided herein are kits for performing the multiplexed assays.

Abstract: The present invention relates to methods of diagnosing an inflammatory disorder in a patient, as well as methods of monitoring the progression of an inflammatory disorder and/or methods of monitoring a treatment protocol of a therapeutic agent or regimen. The invention also relates to assay methods used in connection with the diagnostic methods described herein.

Abstract: Systems (100) and methods for perfusion control in a bioreactor (120) are provided. The system (100) comprises a media container (110) connected to the bioreactor (120) and weighing scales (113, 123) measure weight of the bioreactor (120) and the media container (110). A plurality of controllers (225, 245) are connected to the weighing scales and configured to continuously feed the media from media container (110) to the bioreactor (120) at a user defined rate using a motor pump (112). A filter (130) is provided to receive feed from the bioreactor (120) through a recirculation line (121) and a permeate flow line (141) is connected to the filter (130) to flow out the permeate from the filter (130).

Abstract: Assay cartridges are described that have a detection chamber, preferably having integrated electrodes, and other fluidic components which may include sample chambers, waste chambers, conduits, vents, bubble traps, reagent chambers, thy reagent pill zones and the like. In certain embodiments, these cartridges are adapted to receive and analyze a sample collected on an applicator stick. Also described are kits including such cartridges and a cartridge reader configured to analyze an assay conducted using an assay cartridge.

Abstract: Peripheral blood mononuclear cells (PBMCs) can be used in place of DCs when pulsing with antigens, or antigen and adjuvant combination, and then administered to a subject as a vaccine to induce a protective immune response. The PBMC-based vaccine strategy provides a more marked and enduring protective immune response and is also capable of serving as a multi-organism prophylactic vaccine platform. The vaccine platform may be used to screen vaccine and adjuvant combinations and may also be used to allow for adjuvants that are otherwise unsafe for use in humans as the adjuvant may be removed prior to prophylactic administration of the pulsed PBMCs.

Abstract: The present invention relates to the combination chemotherapy with recombinant lectin protein. The invention specifically relates to the cytotoxic effect of recombinant lectin protein having amino acid sequence of SEQ ID NO: 1 in combination with other therapeutic agents, wherein the other therapeutic agents are anti-cancer agents. The combinations are highly synergistic and efficacious against several cancers.

Abstract: A system, method, and computer program product for providing personalized coordinated shopping among multiple participants in a network marketplace. Social group interactions are extended to shopping, to enhance the scope and efficiency of commerce. A shopping group comprising selected members of a social group includes an authorized purchaser and a number of shoppers who are not authorized to make purchases. A non-authorized purchaser selects desired items and sends a purchase approval request to the authorized purchaser, including a personalized video message describing and supporting the request. The personalized video message is sent to the authorized purchaser by communication means selected according to determined current availability, including via review of a social calendar. The authorized purchaser may approve, decline, or request further information from the requester, upon reviewing the purchase request.